MedPath

Evaluation of safety and efficacy of skin care formulation

Not yet recruiting
Conditions
43 normal skin volunteers and 13 sensitive skin and having wheatish to dark complexion & visible dry skin.
Registration Number
CTRI/2022/08/044896
Lead Sponsor
DPKA Universal Consumer Ventures Private Limited
Brief Summary

PRIMARY OBJECTIVE: The objective of this study will be to assess theefficacy of skin care regime in terms of Skin Brightening Effect on healthyfemale subjects.

SECONDARY OBJECTIVE: To evaluate the in-vivo safety and efficacy of askin care regime in terms of Improvement in Skin Water Barrier Function and inSkin Smoothness on healthy human subjects.

Test Product: SUNSCREEN DROPS: ProductA

The evaluation is performedusing: Subject’s Self Evaluation, Dermatological Evaluation: Safety,Dermatological Evaluation: Efficacy, Chromametry, Tewametry, Illustrativephotographs of face under diffused light.

Total duration of the study: 28 daysfollowing the first application of product.

Kinetics: T0, T+30 minutes afterproduct application, T+7 days, T+14 days and T+28 days

Number of volunteers: 56 (43 normalskin volunteers +13 sensitive skin)

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
Female
Target Recruitment
56
Inclusion Criteria
  • 1.Indian / Asian female subjects 2.Healthy subjects (no infectious and evolutive pathology which could make the subject vulnerable and stop the study, no pathology which could interfere with the study, no symptom in the process of an exploratory checkup) 3.Skin is healthy on the studied anatomic unit (free of eczema, wounds, inflammatory scar….) Specific criteria 4.43 normal skin volunteers +13 sensitive skin (declared through lactic acid sting test).
  • 5.Having wheatish to dark complexion.
  • 6.Having visible dry skin.
Exclusion Criteria
  • 1 Being pregnant or breastfeeding or having stopped to breastfeed in the past three months 2 Having refused to give her assent by not signing the consent form 3 Taking part in another study liable to interfere with this study 4 Being insulin-dependent diabetic or non insulin-dependent diabetic with a recent therapy (less than 6 months) 5 Having a progressive asthma (either under treatment or last fit in the last 2 years) 6 Being epileptic. 7 Having non stabilized thyroid problems (requirement of a stabilized treatment for at least 6 months) 8 Having cutaneous hypersensitivity 9 Having a diagnosed or highly probable allergy to one or several compounds of the cosmetic products. 10 Following a chronic medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol) 11 Having undergone a surgery requiring a general anaesthetic of more than one hour in the past 6 months. 12 Having changed her cosmetic habits in the 14 days preceding the start of the study on the studied anatomic unit 13 Having applied a cosmetic product (included make-up) or skin care product on the studied areas the day of the study (only face cleaned with water is accepted) 14 Refusing to follow the restrictions below during the study: -Do not take part in any family planning activities leading to pregnancy and breastfeeding -Do not take part in another study liable to interfere with this study. -Do not take medicinal treatment comprising any of the following products: aspirin-based products, anti-inflammatories, anti-histamines, corticotherapy, taken by general or local routes (the only medication permitted is paracetamol). -Do not change her cosmetic habits apart from the particular conditions mentioned in the protocol, on the studied anatomic unit. -During the study: Do not use other cosmetic products or skin care products other than the tested products to the studied areas. (only standard facewash is accepted). The day of the measurements: No test product must be used (only face cleaned with water is accepted) Specific criteria 15 Having started, changed or interrupted one hormonal treatment (hormonal contraception, Hormone Replacement Therapy) during the past 3 months. 16 Having started, changed or stopped his/her tobacco consumption (for smokers consuming more than 10 cigarettes per day) in the previous 6 months 17 Having taken a medicinal treatment which could lead to hyper pigmentation (phenytoïn, amiodarone, metals, minocycline…) in the previous 6 months 18 Taking oral supplements with major or minor effect on whitening of skin (e.g. vitamin C, beta carotene…) 19 Having had beauty treatment (e.g. skin cleansing, exfoliation, scrub, mask …) or having applied self-tanning products in the week preceding the start of the study 20 Having applied products with anti-wrinkle action (Retinoic acid, retinol, retinaldehyde, isotretinoin, A.H.A...) in the 2 weeks preceding the start of the study 21 Having applied products with a depigmenting action (hydroquinone or derivates…) in the 4 weeks preceding the start of the study. 22 Having undergone physical and/or chemical treatments of the spots (liquid nitrogen, dry ice, pulsed flash lamp, dermabrasion, chemical peel …) in the previous 6 months 23 Having a suntanned skin on the studied areas which could interfere with the evaluations of the study 24 Refusing to follow the restrictions below during the study:.
  • Do not start, change or stop a hormonal treatment (hormonal contraception, Hormone Replacement Therapy).
  • Do not start a medicinal treatment which could lead to hyper pigmentation.
  • Do not use products or techniques or surgery with a depigmenting.
  • Do not take oral supplements with major or minor effect on whitening of skin (e.g. vitamin C, beta-carotene…).
  • Do not have beauty treatment (e.g. skin cleansing, exfoliation, scrub, mask …) or apply self tanning products action.
  • Do not swim in artificial water bodies (pools, hot tubs etc.…).
  • Do not expose herself to the sun by respecting a strict photo-protection.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
skin brightening, skin safetyBaseline, 30 min after product application, 7 days, 14 days and 28 days
Secondary Outcome Measures
NameTimeMethod
Improvement in SkinWater Barrier Function and in Skin Smoothness

Trial Locations

Locations (1)

Mascot Spincontrol India Pvt. Ltd.

🇮🇳

Mumbai, MAHARASHTRA, India

Mascot Spincontrol India Pvt. Ltd.
🇮🇳Mumbai, MAHARASHTRA, India
Dr Raji Patil
Principal investigator
02243349191
raji@mascotspincontrol.in

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.